This offers a significant new option for clinical routine and potentially for forthcoming coeliac drug trials, as the need for biopsy freezing has been the main hindrance to the wider use of IgA deposit studies in coeliac disease despite its almost 100% accuracy [32]. The gene discussed is CD79A; the disease is celiac disease.